Cancer drugs' share of new FDA approvals doubled this decade thanks to smarter R&D: report

4th September 2019 Uncategorised 0

Pursuing novel mechanisms for treating cancer and validating them with clinical trials has paid off for drug developers, especially as the FDA is speeding up approvals of new treatments for unmet medical needs, a Tufts report concluded.

More: Cancer drugs' share of new FDA approvals doubled this decade thanks to smarter R&D: report
Source: fierce